The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

100

Portfolio companies

61

M&A and IPOs

30

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2020 (NASDAQ:ARQT)
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
NASDAQ: NERV
IPO in 2020 (NASDAQ:PASG)
IPO in 2019 (NASDAQ: PHAT)
NASDAQ: RGNX

Life Sciences News

Passage Bio

Passage Bio Announces Pricing of Initial Public Offering

Arcutis Biotherapeutics

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Frazier Life Sciences Team

Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

Frazier Life Sciences Team

Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

View All News